EOLS
Evolus, Inc.
EOLS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over EOLS overall, supported by lower modeled downside and stronger fundamentals.
EOLS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
EOLS's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EOLS PE Valuation
EOLS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 29x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EOLS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect EOLS to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EOLS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.25 | — |
| Q3 2026 | -$0.46 | +$0.46 |
| Q2 2026 | -$0.51 | +$0.47 |
| Q1 2026 | -$0.66 | +$0.23 |
| Q4 2025 | -$0.80 | +$0.01 |
| Q3 2025 | -$0.92 | -$0.02 |
| Q2 2025 | -$0.98 | -$0.08 |
| Q1 2025 | -$0.89 | +$0.15 |
| Q4 2024 | -$0.81 | +$0.27 |
EOLS is still losing money, but far less than before: $0.46 per share over the past year, against $4.83 at its worst in late 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EOLS on earnings quality, reporting a profit while its opponent remains loss making.
EOLS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78M | +13% |
| Q2 2026 | $84.1M | +21% |
| Q1 2026 | $73.1M | +6.7% |
| Q4 2025 | $90.3M | +14% |
| Q3 2025 | $69M | +13% |
| Q2 2025 | $69.4M | +3.7% |
| Q1 2025 | $68.5M | +15% |
| Q4 2024 | $78.9M | +29% |
EOLS's revenue has grown year over year every quarter since late 2020: $78M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +5.9 points |
| Q2 2026 | -5.4% | +9.3 points |
| Q1 2026 | -9.4% | +13 points |
| Q4 2025 | 4.7% | +7.6 points |
| Q3 2025 | -17% | +8.7 points |
| Q2 2025 | -15% | -3.2 points |
| Q1 2025 | -22% | -7.1 points |
| Q4 2024 | -2.9% | +11 points |
EOLS's operating margin was −11% last quarter, up 5.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EOLS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EOLS on profitability, with a higher operating margin.
EOLS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | +$13.4M |
| Q2 2026 | -$3.6M | +$21.8M |
| Q1 2026 | -$10.4M | +$5.6M |
| Q4 2025 | $11.3M | +160% |
| Q3 2025 | -$15.6M | -$9.6M |
| Q2 2025 | -$25.5M | -$18.5M |
| Q1 2025 | -$16M | -$5.1M |
| Q4 2024 | $4.4M | +624% |
EOLS has burned cash in almost every quarter: −$5M over the past year, against −$53M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EOLS on cash generation, producing positive trailing cash flow while its opponent burns cash.
EOLS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +156K shares |
| 1 year | +2.1% | +1.4M shares |
| 3 years | +16% | +9.1M shares |
| 5 years | +20% | +11.1M shares |
| Available history | +134% | +37.8M shares |
EOLS has 66M diluted shares, up 2.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EOLS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EOLS Net Leverage
EOLS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EOLS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 33.2 | Neutral |
EOLS's weekly RSI is 51 (neutral) and its Stochastic is 33 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EOLS PE vs Healthcare Sector
EOLS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EOLS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.29 | 1.5% below |
| 20 week MA | $7.37 | 2.6% below |
| 50 week MA | $6.31 | 14% above |
| 100 week MA | $7.99 | 10% below |
| 200 week MA | $9.59 | 25% below |
EOLS's trend is mixed: it's above one of its five weekly moving averages, and 25% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EOLS on trend strength, trading above more of its moving averages.
EOLS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $3.55 | -70% |
| 2021 | $3.55 | $6.96 | +96% |
| 2022 | $6.96 | $6.87 | -1.3% |
| 2023 | $6.87 | $10.5 | +53% |
| 2024 | $10.5 | $11.1 | +5.3% |
| 2025 | $11.1 | $6.90 | -38% |
| 2026 YTD | $6.90 | $7.18 | +4.1% |
EOLS has finished lower in three of the last six years. It's up 4.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EOLS on returns for 2026, with the stronger performance.